Plain-English translation of NCT05459090 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This research study examines brain tissue from people with drug-resistant epilepsy who are undergoing surgery. Researchers will study how brain chemicals called neurotransmitters work in epileptic tissue, focusing on understanding the balance between calming and activating signals in the brain. The goal is to find new ways to control seizures that don't respond to current medications.
About one-third of people with epilepsy continue having seizures even after trying multiple medications. This trial exists to understand the deeper brain chemistry problems in drug-resistant epilepsy so scientists can develop entirely new treatment approaches beyond the medications currently available.
You likely qualify if…
You likely don't qualify if…
If you qualify and choose to participate, the researchers will collect a small sample of brain tissue that is already being removed during your scheduled epilepsy surgery — you won't have additional procedures. The tissue will then be studied in the laboratory using specialized equipment to understand how brain chemistry works in your epileptic brain. There are no additional visits or medications required beyond your standard surgical care.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
Italy
Enrollment target
~60 participants
Started
July 2022
Primary completion
February 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Last updated on clinicaltrials.gov in August 2022.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
katiuscia Martinello, Biology
Neuromed IRCCS
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.